Special Drug Use-results Survey for Long-term Use (Fostamatinib)
Recruiting
Observational Study
Chronic Idiopathic Thrombocytopenic Purpura
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 149 (estimated)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with chronic idiopathic thrombocytopenic purpura who are treatment with fostamatinib for the first time.
Contacts